App-Quantinova.ai

COMPARISON OF OUTCOMES WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN CARTITUDE-1 VERSUS STANDARD OF CARE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA PATIENTS IN CLINICAL TRIALS OF DARATUMUMAB

Katja Weisel - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

CLINICALLY IMPORTANT CHANGE IN FACIT-FATIGUE SCORE FOR PATIENTS WITH COLD AGGLUTININ DISEASE: AN ANALYSIS USING THE PHASE 3 CARDINAL AND CADENZA STUDIES

Quentin A. Hill - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

INVESTIGATING THE INCIDENCE OF SECONDARY PRIMARY CANCER IN ACUTE PROMYELOCYTIC LEUKEMIA PATIENTS

Yu-Guang Chen - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute promyelocytic leukemia

Arsenic trioxide

LONG-TERM EFFECTS IN SUBGROUPS OF PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN VERSUS ECULIZUMAB: 48-WEEK ANALYSIS OF PEGASUS PHASE 3 TRIAL

Regis Peffault de Latour - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

REDEFINING LOW RISK HIGH HYPERDIPLOIDY IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA

Anthony Moorman - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

OUTCOME OF RITUXIMAB-POLATUZUMAB-BENDAMUSTINE IN THE TREATMENT OF RELAPSED/ REFRACTORY HIGH GRADE LYMPHOMA AND TRANSFORMED HIGH GRADE LYMPHOMA – A MULTI-CENTRE ANALYSIS.

Lydia Sodhi - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lymphomas

Bendamustine

IMPACT OF UNFAVORABLE GENETICS ON MINIMAL RESIDUAL DISEASE (MRD) RESPONSE TO VENETOCLAX+RITUXIMAB RETREATMENT IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): PHASE 3 MURANO SUBSTUDY

Jenny Qun Wu - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Venetoclax

OPTIC PRIMARY ANALYSIS: A DOSE-OPTIMIZATION STUDY OF 3 STARTING DOSES OF PONATINIB (PON)

Jorge E. Cortes - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

Ponatinib

AUDIT OF CHEMOTHERAPY DISRUPTION DUE TO COVID19 PANDEMIC: PERSPECTIVE FROM A UK DISTRICT GENERAL HOSPITAL

humayun ahmad - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

PACIFICA: A RANDOMIZED, CONTROLLED PHASE 3 STUDY OF PACRITINIB VERSUS PHYSICIAN'S CHOICE IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS AND SEVERE THROMBOCYTOPENIA

John Mascarenhas - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Thrombocytopenia

Hydroxyurea

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN ADOLESCENTS AND YOUNG ADULTS (AYAS) WITH STAGE III OR IV HODGKIN LYMPHOMA: A SUBGROUP ANALYSIS FROM THE PHASE 3 ECHELON-1 STUDY

Andrew P. Grigg - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Adcetris

CILTACABTAGENE AUTOLEUCEL VERSUS SELINEXOR + DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH ≥3 LINES OF PRIOR THERAPY: A MATCHING ADJUSTED INDIRECT COMPARISON

Tom Martin - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

PELABRESIB (CPI-0610) IMPROVED ANEMIA ASSOCIATED WITH MYELOFIBROSIS: INTERIM RESULTS FROM MANIFEST PHASE 2 STUDY

Srdan Verstovsek - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

CPI-0610

CANONICAL WNT SIGNALING-RESPONSIVE ACUTE MYELOID LEUKEMIA CELLS ARE DEPENDENT ON BETA-CATENIN BUT NOT GAMMA-CATENIN FOR CLONAL GROWTH

Adam Leckenby - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

BETIBEGLOGENE AUTOTEMCEL IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA: UPDATED RESULTS FROM HGB-207 (NORTHSTAR-2) AND HGB-212 (NORTHSTAR-3)

Franco Locatelli - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thalassemia

Filgrastim

RELATIONSHIP BETWEEN CORNEAL EXAM FINDINGS, BEST-CORRECTED VISUAL ACUITY (BCVA), AND OCULAR SYMPTOMS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) RECEIVING BELANTAMAB MAFODOTIN

Evangelos Terpos - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

SAFETY OF RAVULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: STUDY 301/302 2-YEAR RESULTS

Austin Kulasekararaj - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (TDT) TREATED IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES.

Andreas E. Kulozik - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thalassemia

Busulfan

DUAL ROLES FOR PROTEOSTATIC TARGETING IN ACUTE MYELOID LEUKAEMIA

William Grey - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

‘A DIFFERENT PERSON ENTIRELY’: ADOLESCENT AND YOUNG ADULTS’ EXPERIENCES RETURNING TO EDUCATION AFTER TREATMENT FOR HAEMATOLOGICAL MALIGNANCIES

Cameron Magrath - European Hematology Association (EHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

45280 Abstracts